share_log

Ladenburg Thalmann Initiates Coverage On Anebulo Pharmaceuticals with Buy Rating, Announces Price Target of $6

Benzinga Real-time News ·  Jul 27, 2022 08:24

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy rating and announces Price Target of $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment